American Century Companies
INZY

American Century Companies’s Inozyme Pharma INZY Stock Holding History

American Century Companies’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-79,349
Closed -$220K – 2913
2024
Q4 		$220K Buy
79,349
+8,263
+12% +$31.4K ﹤0.01% 2767
2024
Q3 		$372K Buy
71,086
+13,986
+24% +$72.6K ﹤0.01% 2571
2024
Q2 		$255K Buy
57,100
+5,673
+11% +$27.5K ﹤0.01% 2680
2024
Q1 		$394K Buy
51,427
+22,732
+79% +$125K ﹤0.01% 2531
2023
Q4 		$122K Buy
28,695
+10,622
+59% +$37.7K ﹤0.01% 2790
2023
Q3 		$75.9K Buy
18,073
+5,873
+48% +$29.9K ﹤0.01% 2758
2023
Q2 		$68K Buy
+12,200
New +$72.1K ﹤0.01% 2738

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

American Century Companies's INZY Position: Q1 2025 in Review

American Century Companies sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 79,349 shares — an estimated $220K sold.

American Century Companies first reported a position in INZY in Q2 2023 and held it in 7 quarters. The position peaked at $394K in Q1 2024. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • American Century Companies reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • American Century Companies sold 79,349 Inozyme Pharma shares in Q1 2025, an estimated $220K.
  • American Century Companies first reported a position in Inozyme Pharma in Q2 2023 and held it in 7 quarters.
  • American Century Companies's Inozyme Pharma position peaked at $394K in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on American Century Companies's 13F filing for Q1 2025, filed 13 May 2025.